Guillaume Lecorps
Chilly, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses.
Journal: Journal of clinical lipidology
Published: June 28, 2019
Effect of Alirocumab on Mortality After Acute Coronary Syndromes.
Journal: Circulation
Published: May 24, 2019
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Journal: The New England journal of medicine
Published: November 08, 2018
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial.
Journal: Journal of the American College of Cardiology
Published: September 25, 2018
Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II).
Journal: The American journal of cardiology
Published: March 31, 2017
Antidrug Antibodies in Patients Treated with Alirocumab.
Journal: The New England journal of medicine
Published: March 18, 2017
Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II.
Journal: Diabetes, obesity & metabolism
Published: October 31, 2016
Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.
Journal: Journal of the American Heart Association
Published: September 15, 2016
Showing 1-8 of 8
Last Updated: 09/26/2026